A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Franchi F, Rollini F, Park Y, Angiolillo DJ.
Expert Opin Drug Saf · systematic review; journal article · DOI 10.1517/14740338.2016.1133585 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för cangrelor. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
24 hitsTransition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.
Schneider DJ.
Coron Artery Dis · review; journal article · DOI 10.1097/mca.0000000000000311Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
Angiolillo DJ, Bhatt DL, Steg PG, Stone GW, White HD, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Mahaffey KW, Harrington RA.
J Thromb Thrombolysis · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1007/s11239-015-1233-3The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Gutierrez JA, Harrington RA, Blankenship JC, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Généreux P, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL, CHAMPION PHOENIX Investigators.
Eur Heart J · comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1093/eurheartj/ehv498Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation.
Schneider DJ, Agarwal Z, Seecheran N, Gogo P.
J Interv Cardiol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1111/joic.12229Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
Rollini F, Franchi F, Angiolillo DJ.
Nat Rev Cardiol · review; journal article · DOI 10.1038/nrcardio.2015.113Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
Judge HM, Buckland RJ, Jakubowski JA, Storey RF.
Platelets · research support, non-u.s. gov't; journal article · DOI 10.3109/09537104.2015.1069809Cangrelor: A Review in Percutaneous Coronary Intervention.
Keating GM.
Drugs · review; journal article · DOI 10.1007/s40265-015-0445-3Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
Tamborini Permunian E, Riva N, Guasti L, Squizzato A.
Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2015.1021330Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA.
JACC Cardiovasc Interv · comparative study; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.jcin.2014.09.025Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor.
Lhermusier T, Baker NC, Waksman R.
Am J Cardiol · review; journal article · DOI 10.1016/j.amjcard.2015.01.551Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials.
Tang Y, Zhang YC, Chen Y, Xiang Y.
Int J Clin Exp Med · research-article; journal articlePharmacodynamic effects during the transition between cangrelor and prasugrel.
Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P.
Coron Artery Dis · controlled clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1097/mca.0000000000000158Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
Waite LH, Phan YL, Spinler SA.
Pharmacotherapy · review; journal article · DOI 10.1002/phar.1471Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.
Sardar P, Nairooz R, Chatterjee S, Mushiyev S, Pekler G, Visco F.
J Thromb Thrombolysis · meta-analysis; review; journal article · DOI 10.1007/s11239-013-0998-5Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P.
JACC Cardiovasc Interv · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jcin.2013.08.017Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Rollini F, Franchi F, Tello-Montoliu A, Patel R, Darlington A, Ferreiro JL, Cho JR, Muñiz-Lozano A, Desai B, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.
JACC Cardiovasc Interv · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jcin.2013.11.019Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis.
Pandit A, Aryal MR, Aryal Pandit A, Jalota L, Hakim FA, Mookadam F, Lee HR, Tleyjeh IM.
EuroIntervention · meta-analysis; comparative study; systematic review; journal article · DOI 10.4244/eijv9i11a226Cangrelor for treatment during percutaneous coronary intervention.
Oestreich JH, Dobesh PP.
Future Cardiol · journal article · DOI 10.2217/fca.13.108Cangrelor for treatment of arterial thrombosis.
Walsh JA, Price MJ.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2014.882319Cangrelor: an emerging therapeutic option for patients with coronary artery disease.
Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, Siller-Matula JM, Jeong YH, Fabiszak T, Andruszkiewicz A, Gurbel PA.
Curr Med Res Opin · review; journal article · DOI 10.1185/03007995.2014.880050Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).
Marino M, Rizzotti D, Leonardi S.
Curr Cardiol Rep · review; journal article · DOI 10.1007/s11886-014-0493-4Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.
Serebruany VL, Pokov AN, Fortmann SD, DiNicolantonio JJ.
Thromb Haemost · research support, non-u.s. gov't; journal article · DOI 10.1160/th13-08-0631Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
Serebruany VL, Sibbing D, DiNicolantonio JJ.
Cardiology · comparative study; research support, non-u.s. gov't; review; journal article · DOI 10.1159/000354876